Description du projet
L’impact du stress en début de vie sur la vie future
Le stress en début de vie (ELS) constitue un facteur de risque majeur de dépression et de deux de ses comorbidités physiques principales: la maladie coronarienne et le diabète. Une recherche suggère que la dépression se développe à partir d’une interaction complexe entre des processus biologiques et physiologiques. Le projet EarlyCause, financé par l’UE, identifiera les contributions biologiques de quatre domaines clés interconnectés: l’épigénétique, l’inflammation, le système neuroendocrinien et le microbiome. Il tiendra compte des effets de facteurs tels que le sexe/genre, la socioéconomie, le mode de vie et le comportement. Ce projet associera des recherches de base, précliniques et cliniques, dont des méthodes d’inférence causale, des modèles animaux de stress potentiel et postnatal, des modèles cellulaires de différents tissus, une bioinformatique intégrante et des méthodes d’apprentissage automatique. Les conclusions permettront d’approfondir notre compréhension des biomarqueurs et des résultats d’innovation en lien avec les nouveaux parcours de soins intégrés.
Objectif
EarlyCause will identify and demonstrate causative mechanisms and molecular pathways linking early life stress (ELS) to depression and two of its main physical comorbidities, namely coronary heart disease and diabetes. The consortium will disentangle the complex biological contributions from four key interconnected domains linked to ELS, namely epigenetics, inflammation, neuroendocrine system, and microbiome. Furthermore, modifying effects of environmental factors such as sex/gender, socioeconomics, lifestyle and behavior will be quantified, thus uncovering potential intervention targets that may reverse the causative mechanisms and reduce the impact of ELS on multi-morbidity development in high-risk individuals.
To achieve the goals of the project, this highly multi-disciplinary and experienced consortium will combine state-of-the-art and novel approaches from basic, pre-clinical and clinical research, including causal inference methods such as Mendelian randomisation, animal models of prenatal and postnatal stress, cellular models in various tissues, and integrative bioinformatics and machine learning methods. The consortium members will also enable access and exploitation of the largest set of European cohorts, comprising rich information on early stressors, biological and omics data, as well as depressive, cardiovascular and metabolic phenotypes. Generated data, tissue samples, experimental protocols and cell lines, as well as best practices, will be compiled and integrated into a new open-access research platform within ELIXIR to support future researchers in the emerging topics of ELS and multi-morbidity.
Finally, the project will ensure the research, clinical and socioeconomic impacts are adequately quantified and translated to allow full exploitation of the identified biomarkers and innovation outputs, in particular in relation to new integrated care pathways taking into account ELS-induced multi-morbidity in clinical practice.
Champ scientifique
Not validated
Not validated
Mots‑clés
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
08007 Barcelona
Espagne